Switzerland will get a “very restricted” supply of BOTH sinemet CR AND the traditional sinemet; essentially L-dopa that has been the center of PD treatment for 50 years.
Press release from Swiss PD org.
Says Merck announced very restricted supply for Switzerland for 2010 too 2011.
Information IMPORTANTE
Pénurie de Sinemet® / Sinemet CR®
En raison d’un problème dans leur chaîne de production/livraison, la société
Merck Sharp & Dohme Ltd. (MSD) a annoncé qu’elle ne pourra livrer les
médicaments antiparkinsonien Sinemet® et Sinemet CR® que de façon très
restrictive et ce, du début 2010 à 2011.
Parkinson Suisse, case postale 123, Gewerbestrasse 12a, 8132 Egg,
Tél. 043 277 20 77, Fax 043 277 20 78, E-Mail: info@parkinson.ch

Meanwhile, back at head office, all is good:
WHITEHOUSE STATION, N.J., - According to an 8-K filing with the U.S. Securities and Exchange Commission, pharmaceutical giant Merck & Co. will cut about 15 percent of its workforce and eliminate approximately 2,500 vacant jobs.
The Whitehouse Station, N.J., company said layoffs will affect all areas of the company worldwide and should be accomplished by the end of 2012. Merck said it will achieve reductions by eliminating duplicative positions in sales, administrative and headquarters offices, as well as from the consolidation of manufacturing plants and research and development operations.
For its 2009 fiscal year Merck reported net income of $12.9 billion, or $5.65 per share, up 65 percent from the previous year. Revenue jumped 15 percent to $27.43 billion.